Table I.
Baseline Characteristics
| n | 30 |
|
| |
| Median Age, range | 62 (47–88) |
|
| |
| Gender | |
| Male | 15 (50%) |
| Female | 15 (50%) |
|
| |
| ECOG PS | |
| 0 | 20 (67%) |
| 1 | 8 (27%) |
| 2 | 2 (7%) |
|
| |
| Histology | |
| Follicular lymphoma | 7 (23%) |
| Marginal Zone lymphoma | 7 (23%) |
| Mantle Cell lymphoma | 6 (20%) |
| Small Lymphocytic lymphoma | 6 (20%) |
| Diffuse Large B-cell lymphoma | 3 (10%) |
| Lymphoplasmacytic lymphoma | 1 (3%) |
|
| |
| Median number of prior therapies | 1 (range 1–7) |
|
| |
| Rituximab-refractory | 8 (27%) |
|
| |
| Refractory to prior cytotoxic chemotherapy | 6 (20%) |
|
| |
| Prior rituximab | 29 (97%) |
|
| |
| Prior R-CHOP-like | 15 (50%) |
|
| |
| Prior R-CVP | 9 (30%) |
|
| |
| Prior fludarabine | 4 (13%) |
|
| |
| Prior autologous SCT | 1 (3%) |
R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CVP=rituximab, cyclophosphamide, vincristine and prednisone; SCT=stem cell transplant